Here's Why Pacific Biosciences Is Tumbling Today

Shares of Pacific Biosciences (NASDAQ: PACB) fell over 14% today as investors grappled with more bad news for long-read DNA sequencing power. The latest twist comes courtesy of the European Patent Office (EPO), which revoked a second patent for the company pertaining to its ability to read long, uninterrupted strands of DNA with its machines.